Work

Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps4595

Authors: Michael B. Atkins, Rupal Satish Bhatt, Martin Henner Voss, Brian I. Rini, Eric Jonasch, Elizabeth R. Plimack, Robert Alter, Rachel Barger, Dawn Wilson, Ty McClure, Ravi Kumar, Kenneth M. Attie, Matthew L. Sherman, Shuchi Sumant Pandya

Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, The University of Texas MD Anderson Cancer Center, Fox Chase Cancer Center, Hackensack University Medical Center, Acceleron Pharma (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597710787

Cites:

Cited by: 1

Related to: 10